COAST-AF
2026
Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation (COAST-AF) Randomized Clinical Trial
In patients with persistent atrial fibrillation, adding low-voltage area ablation to pulmonary vein isolation did not significantly reduce atrial arrhythmia recurrence compared with pulmonary vein isolation alone.
Result
Efficacy: Documented AF, atrial flutter or atrial tachycardia lasting over 30 seconds from day 91 to 18 monthsHR 0.82 (95% CI 0.65-1.04) · P = 0.11
Below 1 favours adding low-voltage area ablation to pulmonary vein isolation, above 1 favours pulmonary vein isolation alone.
- Absolute difference
- 8.1 points
The absolute difference is derived from the event rates.
Also reported: In the prespecified subgroup with low-voltage areas (54% of patients), recurrence was 49.3% vs 69.2% (HR 0.77; 95% CI 0.66-0.91; P = .002), and recurrence over 18 months was 37.0% vs 56.2% (HR 0.77; 95% CI 0.64-0.92). In patients without low-voltage areas, recurrence was 49.6% vs 45.1% (HR 1.09; 95% CI 0.90-1.32). Procedure duration and ablation delivery time were longer with low-voltage area ablation. Safety outcomes were similar between groups.
- Subtopic
- Ablation
- Design
- Multicentre randomised trial (Ottawa Heart Institute; 14 Canadian sites) of pulmonary vein isolation plus ablation of low-voltage atrial areas versus pulmonary vein isolation alone in persistent AF
- Enrolled
- 508 patients
- Source
- Nery PB, Wells GA, et al. JAMA. 2026; published online 8 November.doi 10.1001/jama.2026.24331
Discussion & critique
In this single-blind trial with 18 to 36 months of follow-up, adding low-voltage area ablation to pulmonary vein isolation did not significantly reduce atrial arrhythmia recurrence in the overall population. The benefit appeared in the prespecified subgroup with low-voltage areas, who made up only about half of those enrolled. Because the overall result was neutral, that subgroup result supports a hypothesis rather than proving a benefit. The abstract gives no figures for procedure time or for individual safety events, and its outcome is arrhythmia recurrence rather than clinical events or symptoms.